CDC27 was found to be positively correlated with PD-L1 in T-LBL,31 and FGFR1 was shown to promote tumor immune evasion via the YAP/PD-L1 regulatory axis.32 In our cohort, the HL patient with ERBB4, MAP3K9, NF1, and SMG1 mutations, despite exhibiting high PD-L1 expression and amplification, as well as TIL positivity, achieved SD with a short treatment duration. This evidence concerns the gene FGFR1 and Hodgkins lymphoma.